 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Serc, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~100%[1] |
| Protein binding | <5%[1] |
| Metabolism | Liver[1] |
| Metabolites | • 2-(2-Aminoethyl)pyridine • 2-Pyridylacetic acid[1] |
| Elimination half-life | 3.5 hours[2] |
| Excretion | Urine: 91%[1] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C8H12N2 |
| Molar mass | 136.198 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Betahistine, sold under the brand name Serc among others, is a medication used for vertigo and ringing in the ears including that due to Ménière's disease.[3] Evidence for these uses; however, is weak.[4][5][6] Improvement may take a few days to occur.[2] It is taken by mouth.[3]
Common side effects include headache, nausea, and abdominal discomfort.[3] Safety in pregnancy and breastfeeding is unclear.[3] Betahistine is a H1 histamine agonist and a H3 histamine antagonist.[7] It is believed to work by improving blood flow to the inner ear.[2]
Betahistine was approved for medical use in the 1970s.[7] While approved in the United States in the 1970s, this approval was removed due to a lack of benefit.[7] It remains in use in other countries.[7] It is available as a generic medication.[3] In the United Kingdom 84 doses of 16 mg costs the NHS less than 5 pounds.[3]
References edit
- ^ a b c d e Anthony Dickenson (12 January 2017). Drugs in Neurology. Oxford University Press. pp. 408–409. ISBN 978-0-19-966436-8. Archived from the original on 28 August 2021. Retrieved 6 January 2018.
- ^ a b c Adriana P. Tiziani (1 June 2013). Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 1063–. ISBN 978-0-7295-8162-2. Archived from the original on 28 August 2021. Retrieved 6 January 2018.
- ^ a b c d e f g h i BNF 79 : March 2020. London: Royal Pharmaceutical Society. 2020. p. 453. ISBN 9780857113658.
- ^ Murdin, L; Hussain, K; Schilder, AG (21 June 2016). "Betahistine for symptoms of vertigo". The Cochrane database of systematic reviews (6): CD010696. doi:10.1002/14651858.CD010696.pub2. PMID 27327415.
- ^ Wegner, I; Hall, DA; Smit, AL; McFerran, D; Stegeman, I (28 December 2018). "Betahistine for tinnitus". The Cochrane database of systematic reviews. 12: CD013093. doi:10.1002/14651858.CD013093.pub2. PMID 30908589.
- ^ James, AL; Burton, MJ (2001). "Betahistine for Menière's disease or syndrome". The Cochrane database of systematic reviews (1): CD001873. doi:10.1002/14651858.CD001873. PMID 11279734.
- ^ a b c d Babu, Seilesh; Schutt, Christopher A.; Bojrab, Dennis I. (2019). Diagnosis and Treatment of Vestibular Disorders. Springer. p. 192. ISBN 978-3-319-97858-1. Archived from the original on 2021-08-28. Retrieved 2020-10-07.